Patents by Inventor Jacques Näsström

Jacques Näsström has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220133739
    Abstract: Methods for treating and/or protecting against acute liver failure and other hepatotoxicities in an individual employ a combination of a first active agent comprising N-acetylcysteine and a second active agent comprising a manganese complex selected from the group consisting of (i) a calcium manganese mixed metal complex of N,N?-bis-(pyridoxal-5-phosphate)-ethylenediamine-N,N?-diacetic acid (DPDP) having a molar ratio of calcium to manganese in a range of from 1 to 10, or a pharmaceutically acceptable salt thereof, (ii) a mixture of manganese DPDP (MnDPDP), or a pharmaceutically acceptable salt thereof, and a non-manganese-containing DPDP compound, or (iii) a mixture of manganese pyridoxyl ethylenediamine (MnPLED), or a pharmaceutically acceptable salt thereof, and a non-manganese-containing pyridoxyl ethylenediamine (PLED) compound.
    Type: Application
    Filed: January 14, 2022
    Publication date: May 5, 2022
    Inventors: Jacques NÄSSTRÖM, Sven JACOBSSON, Dennis HENRIKSEN, James VAN ALSTINE
  • Patent number: 11260060
    Abstract: Methods, formulations and kits for treating and/or protecting against acute liver failure and other hepatotoxicities in an individual employ a combination of a first active agent which replenishes, or decreases a loss of, functional glutathione in the individual, and a second active agent comprising a manganese complex selected from the group consisting of (i) a calcium manganese mixed metal complex of N,N?-bis-(pyridoxal-5-phosphate)-ethylenediamine-N,N?-diacetic acid (DPDP) having a molar ratio of calcium to manganese in a range of from 1 to 10, or a pharmaceutically acceptable salt thereof, (ii) a mixture of manganese DPDP (MnDPDP), or a pharmaceutically acceptable salt thereof, and a non-manganese-containing DPDP compound, or (iii) a mixture of manganese pyridoxyl ethylenediamine (MnPLED), or a pharmaceutically acceptable salt thereof, and a non-manganese-containing pyridoxyl ethylenediamine (PLED) compound.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: March 1, 2022
    Assignee: EGETIS THERAPEUTICS AB
    Inventors: Jacques Näsström, Sven Jacobsson, Dennis Henriksen, James Van Alstine
  • Publication number: 20190015424
    Abstract: Methods, formulations and kits for treating and/or protecting against acute liver failure and other hepatotoxicities in an individual employ a combination of a first active agent which replenishes, or decreases a loss of, functional glutathione in the individual, and a second active agent comprising a manganese complex selected from the group consisting of (i) a calcium manganese mixed metal complex of N,N?-bis-(pyridoxal-5-phosphate)-ethylenediamine-N,N?-diacetic acid (DPDP) having a molar ratio of calcium to manganese in a range of from 1 to 10, or a pharmaceutically acceptable salt thereof, (ii) a mixture of manganese DPDP (MnDPDP), or a pharmaceutically acceptable salt thereof, and a non-manganese-containing DPDP compound, or (iii) a mixture of manganese pyridoxyl ethylenediamine (MnPLED), or a pharmaceutically acceptable salt thereof, and a non-manganese-containing pyridoxyl ethylenediamine (PLED) compound.
    Type: Application
    Filed: January 10, 2017
    Publication date: January 17, 2019
    Applicant: PledPharma AB
    Inventors: Jacques NÄSSTRÖM, Sven JACOBSSON, Dennis HENRIKSEN, James VAN ALSTINE
  • Patent number: 10111893
    Abstract: Methods for treatment of a pathological condition caused by oxidative stress in a patient comprise administering to the patient a mixed metal complex of a compound of Formula I, or a salt thereof, in an amount effective to reduce the oxidative stress. Pharmaceutical compositions are formed by suspending or dissolving a mixed metal complex of a compound of Formula I, or a salt thereof, in a liquid medium, optionally with one or more physiologically acceptable excipients. The mixed metals comprise calcium and manganese in a molar ratio of calcium to manganese in the range of 1-10: wherein X, R1, R2, R3, and R4 are as defined herein.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: October 30, 2018
    Assignee: PLEDPHARMA AB
    Inventors: Jan-Olof Karlsson, Karl Reineke, Tino Kurz, Rolf Andersson, Michael Hall, Christina McLaughlin, Sven Jacobsson, Jacques Näsström
  • Publication number: 20170165281
    Abstract: Methods for treatment of a pathological condition caused by oxidative stress in a patient comprise administering to the patient a mixed metal complex of a compound of Formula I, or a salt thereof, in an amount effective to reduce the oxidative stress. Pharmaceutical compositions are formed by suspending or dissolving a mixed metal complex of a compound of Formula I, or a salt thereof, in a liquid medium, optionally with one or more physiologically acceptable excipients. The mixed metals comprise calcium and manganese in a molar ratio of calcium to manganese in the range of 1-10: wherein X, R1, R2, R3, and R4 are as defined herein.
    Type: Application
    Filed: February 28, 2017
    Publication date: June 15, 2017
    Inventors: Jan-Olof Karlsson, Karl Reineke, Tino Kurz, Rolf Andersson, Michael Hall, Christina McLaughlin, Sven Jacobsson, Jacques Näsström
  • Patent number: 9597334
    Abstract: Methods for treatment of a pathological condition caused by oxidative stress in a patient comprise administering to the patient a mixed metal complex of a compound of Formula I, or a salt thereof, in an amount effective to reduce the oxidative stress. The mixed metals comprise calcium and manganese in a molar ratio of calcium to manganese in the range of 1-10: wherein X, R1, R2, R3, and R4 are as defined herein.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: March 21, 2017
    Assignee: PLEDPHARMA AB
    Inventors: Jan-Olof Karlsson, Karl Reineke, Tino Kurz, Rolf Andersson, Michael Hall, Christina McLaughlin, Sven Jacobsson, Jacques Näsström
  • Publication number: 20160038507
    Abstract: Methods for treatment of a pathological condition caused by oxidative stress in a patient comprise administering to the patient a mixed metal complex of a compound of Formula I, or a salt thereof, in an amount effective to reduce the oxidative stress. The mixed metals comprise calcium and manganese in a molar ratio of calcium to manganese in the range of 1-10: wherein X, R1, R2, R3, and R4 are as defined herein.
    Type: Application
    Filed: October 26, 2015
    Publication date: February 11, 2016
    Inventors: Jan-Olof Karlsson, Karl Reineke, Tino Kurz, Rolf Andersson, Michael Hall, Christina McLaughlin, Sven Jacobsson, Jacques Näsström
  • Patent number: 9187509
    Abstract: A mixed metal complex of a compound of Formula I, or a salt thereof, wherein the mixed metals comprise a Group III-XII transition metal and a Group II metal: wherein X, R1, R2, R3, and R4 are as defined herein, is produced in a one step crystallization from a solution of the Group III-XII transition metal, the Group II metal, and a compound of Formula I. Methods for treatment of a pathological condition in a patient, for example, a pathological condition caused by the presence of oxygen-derived free radicals, comprise administering the mixed metal complex to the patient.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: November 17, 2015
    Assignee: Pled Pharma AB
    Inventors: Jan-Olof Karlsson, Karl Reineke, Tino Kurz, Rolf Andersson, Michael Hall, Christina McLaughlin, Sven Jacobsson, Jacques Näsström
  • Publication number: 20150005259
    Abstract: A mixed metal complex of a compound of Formula I, or a salt thereof, wherein the mixed metals comprise a Group III-XII transition metal and a Group II metal: (Formula I) (I) wherein X, R1, R2, R3, and R4 are as defined herein, is produced in a one step crystallization from a solution of the Group III-XII transition metal, the Group II metal, and a compound of Formula I. Methods for treatment of a pathological condition in a patient, for example, a pathological condition caused by the presence of oxygen-derived free radicals, comprises administering the mixed metal complex to the patient.
    Type: Application
    Filed: December 4, 2012
    Publication date: January 1, 2015
    Inventors: Jan-Olof Karlsson, Karl Reineke, Tino Kurz, Rolf Andersson, Michael Hall, Christina McLaughlin, Sven Jacobsson, Jacques Nasstrom